Welcome to our dedicated page for Nuvation Bio SEC filings (Ticker: NUVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvation Bio Inc. filings document the regulatory record of a public oncology company with Class A common stock listed on the New York Stock Exchange. The company's 8-K disclosures cover operating and financial results, material agreements, clinical and regulatory updates for taletrectinib and safusidenib, pipeline decisions involving its drug-drug conjugate program, and other material-event disclosures.
Proxy materials describe board elections, auditor ratification, executive compensation votes, shareholder voting procedures, and governance matters. Capital-structure filings identify the company's registered securities, including Class A common stock and historical warrant-related disclosures, while Form 25 records document removal of a warrant class from exchange listing and registration.
Nuvation Bio Inc. (NUVB) reported insider transactions by its Chief Medical Officer. On 11/25/2025, the officer exercised 10,000 stock options for Class A common stock at $3.61 per share and sold 10,000 shares at $7.50 per share, leaving 18,000 shares directly owned. On 11/26/2025, the officer again exercised 10,000 options at $3.61 and sold 10,000 shares at $8.00, with direct ownership again reported as 18,000 shares. These trades came from stock options with a $3.61 exercise price and an expiration date of 07/14/2032. After the reported option exercises, the officer still holds 470,000 stock options, which continue to vest monthly following an initial 25% vest on the one-year anniversary of 07/15/2022.
Nuvation Bio Inc. announced it is discontinuing development of NUV-1511, the first compound from its drug-drug conjugate platform, due to a lack of sufficiently consistent efficacy across patient cohorts, despite being well tolerated and showing promising signals in some patients. The company plans to use knowledge from this program to design new DDC candidates and will reallocate the $100-150 million of projected NUV-1511 R&D and CMC costs through 2029 to other pipeline molecules and next-generation DDC programs. Nuvation Bio highlighted ongoing initiatives, including a global randomized G203 trial of safusidenib in high-risk IDH1-mutant glioma and continued investment in the commercial launch and development of IBTROZI (taletrectinib), such as the TRUST-IV study in early-stage ROS1+ non-small cell lung cancer. The company also furnished an updated corporate presentation to accompany these updates.
NUVB filed a notice that an affiliated holder, named in the form, plans to sell 10,000 shares of Class A common stock through Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $75,000.00. The filing states that these shares were acquired on 11/25/2025 by exercising options under a registered plan, paid in cash.
The notice also lists recent sales for the same seller over the past three months, including 20,000 common shares sold on 11/20/2025 for gross proceeds of $140,074.00, 15,000 Class A common shares sold on 11/19/2025 for $76,552.50, and 15,000 Class A common shares sold on 11/17/2025 for $71,475.00. Shares of Class A common stock outstanding were reported as 342,833,433.
Nuvation Bio Inc. (NUVB) Chief Scientific Officer reported option exercises and same-day share sales. On 11/20/2025, the insider exercised 69,051 stock options at $1.74 per share and 300,000 stock options at $1.94 per share, receiving the same number of Class A common shares.
That same day, the insider sold 69,051 and 300,000 Class A common shares at a weighted-average price of $7.227 per share in separate transactions, leaving 0 shares of common stock directly owned afterward. Following these transactions, the insider continued to hold 229,884 options with a $1.74 exercise price expiring on 01/21/2030 and 200,000 options with a $1.94 exercise price expiring on 02/27/2033.
Nuvation Bio Inc. (NUVB) reported an insider equity transaction by its Chief Medical Officer. On 11/20/2025, the officer exercised a stock option to buy 20,000 shares of Class A common stock at $1.87 per share and then sold 20,000 shares of Class A common stock in an open-market transaction at a weighted-average price of $7.0037 per share. After these transactions, the officer beneficially owned 18,000 shares of Class A common stock directly and held 450,000 stock options with an exercise price of $1.87 per share, expiring on 02/27/2034. The option vests 25% on the one-year anniversary of 02/29/2024 and monthly over the following 36 months, subject to continuous service.
Nuvation Bio Inc. (NUVB) reported an insider transaction by its Chief Technical Operations officer. On 11/19/2025, the officer exercised 200,000 stock options at an exercise price of $1.87 per share, converting them into Class A common stock. On the same date, the officer sold 200,000 Class A common shares at a weighted-average price of $7.1384 per share. After these transactions, the officer directly held 24,000 shares of Class A common stock and 300,000 stock options. The filing notes additional shares acquired through the company’s 2021 Employee Stock Purchase Plan and describes the vesting schedule for the option grant.
A shareholder of NUVB has filed a Rule 144 notice to sell up to 369,051 common shares through broker Morgan Stanley Smith Barney LLC on the NYSE. The filing lists an aggregate market value of 2,667,131.58 for these shares, compared with 342,833,433 common shares outstanding. The shares come from the exercise of stock options under a registered plan, with lots of 300,000 and 69,051 options exercised for cash on 11/20/2025. The notice also discloses that Gary Hattersley sold 100,000 common shares for gross proceeds of 502,460.00 on 10/27/2025 during the prior three months.
An affiliate of NUVB has filed a Form 144 notice to sell 20,000 shares of Class A common stock. The shares are planned to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $140,074.00. The filing lists 342,833,433 shares of Class A common stock outstanding and shows that the 20,000 shares were acquired on 11/20/2025 by exercising options under a registered plan for cash. The seller, Dongfang Liu, also sold 15,000 Class A shares on 11/17/2025 and 15,000 shares on 11/19/2025 in the prior three months.
Nuvation Bio Inc. (NUVB) reported insider transactions by its Chief Medical Officer on Form 4. On 11/17/2025 and 11/19/2025, the officer exercised stock options to buy a total of 30,000 shares of Class A common stock at an exercise price of $1.87 per share and sold 30,000 shares in open-market transactions.
The sales included 15,000 shares on 11/17/2025 at $4.765 per share and 15,000 shares on 11/19/2025 at a weighted-average price of $5.1035 per share. After these transactions, the officer beneficially owned 18,000 shares of Class A common stock and held 470,000 stock options with a $1.87 exercise price expiring on 02/27/2034.
NUVB shareholder files notice to sell common shares under Rule 144. A holder of Class A common stock plans to sell 15,000 shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $76,552.50. These shares were acquired on 11/19/2025 by exercising options under a registered plan for cash and will be sold as freely tradable stock. The notice also reports a prior sale over the past three months of 15,000 Class A common shares on 11/17/2025 for gross proceeds of $71,475. The form includes a representation that the selling holder is not aware of any undisclosed material adverse information about NUVB’s operations.